This study is looking at new ways to treat HER2-positive gastric cancer (stomach cancer) or gastroesophageal junction adenocarcinoma (cancer where the esophagus meets the stomach). You might be able to join if your cancer is HER2-positive and has a PD-L1 combined positive score (CPS) of 1 or higher, and you haven't received treatment for it yet. The study is comparing different combinations of medicines: rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan, against trastuzumab with chemotherapy and pembrolizumab. There's also a group looking at rilvegostomig with trastuzumab and chemotherapy. The main goals are to see how long people live without their cancer getting worse (progression-free survival) and how long people live overall (overall survival), both measured for up to about 6 years. This study is currently recruiting 840 participants.

Study design

This is a Phase 3, randomized, open-label, Sponsor-blinded study with three groups, involving 840 participants globally.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to approximately 6 years to measure how long they live without their cancer getting worse and how long they live overall.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.